UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____to _____ Commission File Number: 001-40261 Soluna Holdings, Inc. (Exact name of registrant as specified in its charter) __________________ Nevada 14-1462255 State o ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-42472 PLUM ACQUISITION CORP. IV (Exact name of registrant as specified in its charter) Cayman Islands 98-1795710 (State or othe ...

(Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 2021 Fillmore St. #2089 For the transition period from to Commission File Number: 001-42472 PLUM ACQUISITION CORP. IV (Exact name of registrant as specified in its charter) Cayman Islands 9 ...

Financial Performance - Revenues for Q1 2025 were $401 thousand, a decrease of $701 thousand or 63.6% compared to $1,102 thousand in Q1 2024[100] - Gross profit for Q1 2025 was $196 thousand, down $241 thousand or 55.1% from $437 thousand in Q1 2024, with a profit margin increase to 48.9%[101] - The net loss for Q1 2025 was $2,076 thousand, an increase of $968 thousand or 87.4% compared to a net loss of $1,108 thousand in Q1 2024[100] Expenses - Research and development expenses increased by $166 thousand or 59.1% in Q1 2025, primarily due to higher product development costs[103] - General and administrative expenses rose by $598 thousand or 42.5% in Q1 2025, largely due to increased legal fees related to regulatory inquiries[104] Cash Flow and Capital - Cash and cash equivalents decreased by $1,169 thousand to $12,866 thousand as of March 31, 2025, primarily due to the net loss[106] - Working capital as of March 31, 2025, was $11,099 thousand, down from $12,809 thousand at the end of 2024[107] - Operating activities for Q1 2025 resulted in cash outflows of $1,111 thousand, primarily due to the net loss of $2,076 thousand[108] - Financing activities for the three months ended March 31, 2025, resulted in cash outflows of $17 thousand, primarily due to $41 thousand in tax disbursements for employee restricted stock units, partially offset by $24 thousand in net proceeds from warrant exercises[111] - The company has raised approximately $105.3 million in gross proceeds through equity securities since inception, with ongoing needs for additional capital[86] Compliance and Regulatory Issues - The company received a notice from Nasdaq indicating it no longer meets the minimum bid price requirement of $1 per share, with a compliance period until September 29, 2025[94][95] - The company is at risk of delisting from Nasdaq if it fails to comply with the minimum closing bid price requirement of $1.00 per share by September 29, 2025[122] - The company has been granted 180 calendar days to regain compliance with Nasdaq's listing requirements[123] Internal Controls and Legal Matters - As of March 31, 2025, the company maintained effective disclosure controls and procedures at a reasonable assurance level[115] - No changes in internal control over financial reporting occurred during the quarter ended March 31, 2025, that materially affected internal controls[116] - The management does not expect that the disclosure controls and procedures will prevent or detect all errors and fraud due to inherent limitations[118] - The company is currently not aware of any legal proceedings that may materially affect its business or financial condition[120] - The company is subject to risks associated with proxy contests and actions from activist stockholders, which could interfere with its business plan[124] Stock Issuance - On March 31, 2025, the company issued 3,750 shares of common stock at a fair market value of $0.94 per share from its 2013 Consultant Stock Plan[127] Off-Balance Sheet Transactions - There were no off-balance sheet transactions reported[112]

Exhibit 1.1 AT THE MARKET OFFERING AGREEMENT April 28, 2025 Roth Capital Partners, LLC 888 San Clemente Drive, Suite 400 Newport Beach, CA 92660 Ladies and Gentlemen: Aptevo Therapeutics Inc., a corporation organized under the laws of Delaware (the "Company"), confirms its agreement (this "Agreement") with Roth Capital Partners, LLC (the "Manager") as follows: "Action" shall have the meaning ascribed to such term in Section 3(p). "Affiliate" shall have the meaning ascribed to such term in Section 3(o). "App ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________. Commission File Number: 001-38298 Zomedica Corp. (Exact name of registrant as specified in its charter) Alberta, Canada N/A (S ...

Financial Performance - For the three months ended March 31, 2025, total revenue increased by $2,874, or 9.9%, to $31,815 compared to $28,941 in the same period of 2024[148]. - Net income for the three months ended March 31, 2025, was $4,020 million, compared to a net loss of $103,358 million for the same period in 2024[168]. - Net income from continuing operations improved by $16,717 to $3,997, compared to a net loss of $12,720 in the prior period[147]. - Adjusted EBITDA for the three months ended March 31, 2025, was $9,710 million, a significant improvement from a loss of $848 million in the same period of 2024[168]. - Income from continuing operations was $3,997 million for the three months ended March 31, 2025, compared to a loss of $12,720 million in the same period of 2024[168]. Revenue and Profitability - Digital revenue increased by 10.3% to $31,608, driven by a $4,118 increase in performance marketing revenue and a $1,001 increase in publisher revenue[151]. - Gross profit for the same period was $15,669, an increase of $6,736, representing a 75.4% increase from $8,933 in 2024, with a gross profit percentage of 49.3% compared to 30.9% in 2024[148][149]. - The segment revenue for Finance increased by $1,829, primarily driven by an increase in performance marketing revenues[156]. - The segment gross profit increased to $18,552, up $3,661 from $14,891 in 2024, with notable increases in all segments[158]. Expenses and Costs - Operating expenses decreased by $8,577, or 50.8%, to $8,307, primarily due to reductions in headcount and consulting spend[148]. - Selling and marketing expenses decreased by $2,430, or 53.2%, to $2,134, representing 7% of revenues compared to 16% in 2024[153]. - General and administrative expenses decreased by $4,852, or 47.9%, to $5,283, representing 17% of revenues compared to 35% in 2024[154]. - Interest expense decreased by $1,335, or 30.8%, to $3,004, primarily due to lower amortization of debt costs and lower interest charges[164]. - Depreciation and amortization expenses were $2,166 million for the three months ended March 31, 2025, compared to $2,536 million for the same period in 2024[168]. - Stock-based compensation costs were $182 million for the three months ended March 31, 2025, down from $913 million in the same period of 2024[168]. Cash Flow and Working Capital - Net cash provided by operating activities for the three months ended March 31, 2025, was $3,662, compared to a net cash used of $1,965 in the same period of 2024[144]. - Cash and cash equivalents at the end of the period for March 31, 2025, were $2,902, down from $4,003 at the end of March 31, 2024[144]. - As of March 31, 2025, the working capital deficit was $80,622, a slight improvement from $82,022 as of December 31, 2024[143]. Discontinued Operations and Impairments - Total liabilities from discontinued operations were $96,056 as of March 31, 2025, following the discontinuance of the Sports Illustrated media business[140]. - The company recorded a loss on impairment of assets of $1,198 million for the three months ended March 31, 2024, with no such loss reported for the same period in 2025[168]. Strategic Developments - The company entered into a Membership Purchase Agreement to acquire 100% of TravelHost LLC for $1.0 million on May 12, 2025[125]. - The company is closely monitoring macroeconomic conditions, including inflation and geopolitical factors, which may adversely affect its business[126]. Taxation - The provision for income taxes increased to $286 million for the three months ended March 31, 2025, compared to $41 million for the same period in 2024, reflecting an increase of $245 million due to improved operating results[166]. Digital Advertising - For the three months ended March 31, 2025, digital advertising revenue decreased by approximately 4% compared to the same period in fiscal 2024[127]. - RPM increased by 20% to $22.21 for the three months ended March 31, 2025, up from $18.56 in the same period of 2024, driven by higher video advertising sales[131]. - Monthly average pageviews rose by 15% to 327,510,084 for the three months ended March 31, 2025, compared to 286,009,299 in the same period of 2024[131].

Financial Performance - For the fiscal second quarter ended March 31, 2025, Outlook Therapeutics reported a net loss of $46.4 million, or $1.50 per share, compared to a net loss of $114.3 million, or $8.01 per share, for the same period last year[11]. - The adjusted net loss for the fiscal second quarter was $12.5 million, or $0.40 per share, down from an adjusted net loss of $22.1 million, or $1.55 per share, in the fiscal second quarter of 2024[11]. - For the three months ended March 31, 2025, the net loss attributable to common stockholders was $46.358 million, compared to a net loss of $114.289 million for the same period in 2024, representing a 59.3% improvement[26]. - The adjusted net loss attributable to common stockholders (non-GAAP) for the three months ended March 31, 2025, was $12.450 million, compared to $22.057 million in 2024, a reduction of 43.5%[26]. - The company reported a loss from operations of $12.391 million for the three months ended March 31, 2025, compared to a loss of $18.940 million in the same period of 2024, a 34.5% decrease[26]. - The loss before income taxes for the six months ended March 31, 2025, was $28.977 million, a significant improvement from $125.464 million in the same period of 2024, representing a 77.0% reduction[26]. Cash and Assets - As of March 31, 2025, Outlook Therapeutics had cash and cash equivalents of $7.6 million[13]. - Cash and cash equivalents decreased to $7.556 million as of March 31, 2025, from $14.928 million in 2024, a decline of 49.3%[24]. - Total assets decreased to $19.075 million as of March 31, 2025, from $28.823 million in 2024, a decline of 33.7%[24]. - The total stockholders' deficit decreased to $32.463 million as of March 31, 2025, from $73.077 million in 2024, reflecting a 55.6% improvement[24]. Product Development and Regulatory Approvals - The FDA has set a PDUFA goal date of August 27, 2025, for the approval of ONS-5010 (bevacizumab-vikg) for the treatment of wet AMD[8]. - LYTENAVA™ is the first authorized ophthalmic formulation of bevacizumab for treating wet AMD in the EU and UK, with approximately 2.8 million injections annually in Europe and 2.7 million in the U.S. for retinal diseases[6]. - The BLA resubmission for ONS-5010 was based on data from the NORSE EIGHT trial, which demonstrated efficacy and safety for the treatment of wet AMD[9]. - If approved, ONS-5010/LYTENAVA™ will receive 12 years of regulatory exclusivity in the United States[8]. - The company may seek authorization for LYTENAVA™ in other European countries, Japan, and additional markets[7]. Strategic Collaborations and Launch Plans - The company is on track for the commercial launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK in Q2 CY2025, following marketing authorizations granted in May 2024 and July 2024[3][4]. - Outlook Therapeutics has entered into a strategic collaboration with Cencora to support the global commercial launch of LYTENAVA™ following regulatory approvals[7]. Research and Development Expenses - Research and development expenses for the six months ended March 31, 2025, were $14.067 million, down from $18.038 million in the same period of 2024, indicating a 22.0% decrease[26]. - The company incurred warrant inducement expenses of $33.857 million for the three months ended March 31, 2025, compared to no such expenses in the same period of 2024[26].

Company Growth and Acquisitions - AgEagle achieved significant growth by acquiring three market-leading companies in 2021, enhancing its portfolio of UAS airframes, sensors, and software for commercial and government use[119] - The company has successfully integrated these acquisitions, resulting in a unified global company focused on advancing autonomous flight performance[119] - The company intends to accelerate growth through strategic acquisitions of technologically advanced UAS companies, enhancing its market position and revenue potential[122] Product Development and Innovation - AgEagle's eBee fixed-wing drones have completed over one million flights in the past decade, serving various industries including agriculture, military, and environmental monitoring[127] - AgEagle's new RedEdge-P dual sensor drone, released in May 2023, enhances aerial imaging capabilities and is designed for environmental monitoring and vegetation analysis[126] - The eBee X series of drones are the first to comply with Category 3 of the sUAS Over People rules published by the FAA, facilitating broader operational capabilities[128] - AgEagle's workforce is comprised of approximately 70% engineers and data scientists, providing a competitive advantage in technology development and innovation[124] Government Contracts and Approvals - In April 2023, AgEagle was awarded a five-year Multiple Award Schedule (MAS) Contract by the U.S. federal government's GSA, enhancing its penetration into the government sector[127] - The eBee TAC UAS has been approved for procurement by the Department of Defense, positioning it as a critical tool for military and government agencies[128] Financial Performance - For the three months ended March 31, 2025, revenues were $3,649,410, a decrease of $245,037 or 6.3% compared to $3,894,447 for the same period in 2024, primarily due to decreased sensor sales and SaaS revenue[134] - Cost of sales decreased by $424,433 or 21.9% to $1,515,592 for the three months ended March 31, 2025, while gross profit increased by $179,396 or 9.2% to $2,133,818, attributed to a higher mix of drone sales[135] - Operating expenses were reduced by $1,211,947 or 27.9% to $3,136,363 for the three months ended March 31, 2025, driven by staff attrition and lower consulting fees[136] - General and administrative expenses decreased by $709,847 or 26.5% to $1,972,811, mainly due to reduced compensation expenses and lower legal and accounting costs[138] - Research and development expenses fell by $393,818 or 34.8% to $736,411, primarily due to the integration of R&D teams[139] - Net income for the three months ended March 31, 2025, was $7,060,039, an increase of $13,375,626 or 211.8% compared to a net loss of $6,315,587 for the same period in 2024[142] Cash Flow and Liquidity - Cash on hand as of March 31, 2025, was $3,784,659, an increase of $170,663 or 4.7% from $3,613,996 as of December 31, 2024[143] - Cash used in operations decreased by $258,537 or 16.6% to $1,294,556 for the three months ended March 31, 2025, due to reduced operating loss[144] - The company reported a working capital of $5,383,426 as of March 31, 2025, but indicated a need for additional liquidity to meet financial obligations over the next twelve months[147][148] - The company has no off-balance sheet arrangements that could materially affect its financial condition as of March 31, 2025[149] Quality Management - The company plans to achieve ISO:9001 international certification for its Quality Management System by Q2 2025, reflecting its commitment to quality and safety standards[124]

Exhibit 99.1 BARNWELL INDUSTRIES, INC. P R E S S R E L E A S E 1100 Alakea Street, Suite 500 Honolulu, Hawaii 96813 Telephone (808) 531-8400 Fax (808) 531-7181 Website: www.brninc.com Barnwell Industries, Inc. Reports Results for its Second Quarter Ended March 31, 2025 HONOLULU, HAWAII, May 15, 2025 -- Barnwell Industries, Inc. (NYSE American: BRN) today reported financial results for its second quarter ended March 31, 2025. For the quarter, the Company had revenue from continuing operations of $3,569,000 a ...